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A bs tr ac t
Background
Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in 
patients with venous thromboembolism is unclear.
Methods
In a randomized, double-blind, noninferiority study, we randomly assigned patients 
with acute venous thromboembolism, who had initially received heparin, to receive 
edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of 
patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 
60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. 
The primary efficacy outcome was recurrent symptomatic venous thromboembolism. 
The principal safety outcome was major or clinically relevant nonmajor bleeding.
Results
A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pul-
monary embolism. Among patients receiving warfarin, the time in the therapeutic 
range was 63.5%. Edoxaban was noninferior to warfarin with respect to the pri-
mary efficacy outcome, which occurred in 130 patients in the edoxaban group 
(3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% con-
fidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome 
occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in 
the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P = 0.004 for superiority). 
The rates of other adverse events were similar in the two groups. A total of 938 pa-
tients with pulmonary embolism had right ventricular dysfunction, as assessed by 
measurement of N-terminal pro–brain natriuretic peptide levels; the rate of recur-
rent venous thromboembolism in this subgroup was 3.3% in the edoxaban group 
and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98).
Conclusions
Edoxaban administered once daily after initial treatment with heparin was non inferior 
to high-quality standard therapy and caused significantly less bleeding in a broad 
spectrum of patients with venous thromboembolism, including those with severe 
pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov 
number, NCT00986154.)
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Venous thromboembolism is the third most common cardiovascular disease after myocardial infarction and stroke, affecting at 
least 700,000 persons annually in North America.1-3 
The standard treatment consists of low-molecular-
weight heparin followed by vitamin K antagonists.4 
A number of studies have established that new 
oral anticoagulants with or without initial hepa-
rin therapy are effective alternatives.5-8
Edoxaban is a direct inhibitor of activated fac-
tor X with a rapid onset of action. It is admin-
istered orally once daily and has proven anti-
thrombotic efficacy.9-11 The Hokusai-VTE study 
was a randomized, double-blind clinical trial that 
was conducted to evaluate edoxaban for the treat-
ment of venous thromboembolism. The study was 
designed with the aim of broadening applicability 
to real-world practice and encouraging the enroll-
ment of all patients, including those with exten-
sive disease, by specifying that treatment should 
be initiated with the proven, global standard of 
parenteral heparin; that the dose of the study 
drug should be halved in patients perceived to be 
at higher risk for bleeding (e.g., those with renal 
impairment or low body weight); and that physi-
cians should be allowed to adjust the duration of 
treatment after 3 months according to their clini-
cal judgment or in keeping with evolving evidence. 
In addition, patients were followed for 12 months 
regardless of the duration of therapy to compare 
the clinical outcomes of the two study regimens.
Me thods
Study Oversight
In this randomized, double-blind trial, we com-
pared heparin (enoxaparin or unfractionated 
heparin) followed by edoxaban with heparin fol-
lowed by warfarin with respect to efficacy and 
safety in patients with deep-vein thrombosis, 
pulmonary embolism, or both.12 A coordinating 
committee in collaboration with the sponsor 
(Daiichi Sankyo) was responsible for the design 
and oversight of the study and for developing the 
protocol. The institutional review board at each 
participating center approved the protocol. All 
patients provided written informed consent. The 
sponsor was responsible for the collection and 
maintenance of the data. An independent com-
mittee, whose members were unaware of the 
study-group assignments, adjudicated all sus-
pected outcomes and the results of baseline im-
aging tests and assessed the anatomical extent of 
thrombosis. An independent data and safety mon-
itoring committee periodically reviewed study out-
comes. The members of the writing committee 
wrote all drafts of the manuscript (no one who is 
not a named author contributed substantially to 
the manuscript), verified the data, and vouch for 
the completeness of the data, the accuracy of the 
analyses, and the fidelity of the study to the proto-
col. The protocol and accompanying documents 
are available with the full text of this article at 
NEJM.org.
Patients
Patients 18 years of age or older were eligible if 
they had objectively diagnosed, acute, symptom-
atic deep-vein thrombosis involving the popliteal, 
femoral, or iliac veins or acute, symptomatic pul-
monary embolism (with or without deep-vein 
thrombosis). Patients were excluded if they had 
contraindications to heparin or warfarin, had 
received treatment for more than 48 hours with 
therapeutic doses of heparin, had received more 
than one dose of a vitamin K antagonist, had 
cancer for which long-term treatment with low-
molecular-weight heparin was anticipated, had 
another indication for warfarin therapy, contin-
ued to receive treatment with aspirin at a dose of 
more than 100 mg daily or dual antiplatelet ther-
apy, or had creatinine clearance of less than 30 ml 
per minute. The full list of exclusion criteria is pro-
vided in the protocol.
Randomization and Study Treatment
Randomization was performed with the use of 
an interactive Web-based system, with stratifica-
tion according to the qualifying diagnosis (deep-
vein thrombosis or pulmonary embolism), pres-
ence or absence of temporary risk factors, and 
the dose of edoxaban. All patients received initial 
therapy with open-label enoxaparin or unfrac-
tionated heparin for at least 5 days.12 Edoxaban 
or warfarin was administered in a double-blind, 
double-dummy fashion.
Edoxaban (or placebo) was started after dis-
continuation of initial heparin. Edoxaban was ad-
ministered at a dose of 60 mg orally once daily, 
taken with or without food, or at a dose of 30 mg 
once daily in patients with a creatinine clearance 
of 30 to 50 ml per minute or a body weight of 
60 kg or less or in patients who were receiving 
concomitant treatment with potent P-glycoprotein 
inhibitors.
Warfarin (or placebo) was started concurrently 
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with the study regimen of heparin, with adjust-
ment of the dose to maintain the international 
normalized ratio (INR) between 2.0 and 3.0. All 
measurements were performed by means of a 
point-of-care device that provided an actual INR 
value for patients receiving warfarin and a sham 
INR value for patients receiving edoxaban.12 INR 
measurements were required to be performed at 
least monthly.
Treatment with edoxaban or warfarin was to 
be continued for at least 3 months in all patients 
and for a maximum of 12 months. The duration 
was determined by the treating physician on the 
basis of the patient’s clinical features and pa-
tient preference.
Outcome Measures
The primary efficacy outcome was the incidence 
of adjudicated symptomatic recurrent venous 
thromboembolism, which was defined as a com-
posite of deep-vein thrombosis or nonfatal or fa-
tal pulmonary embolism. Death was adjudicated 
as related to venous thromboembolism, other 
cardiovascular disease, bleeding, or other causes. 
Pulmonary embolism was considered to be the 
cause of death if there was objective documenta-
tion that a pulmonary embolism caused the death 
or if the death could not be attributed to a docu-
mented cause and pulmonary embolism could 
not be ruled out. Prespecified secondary efficacy 
outcomes included the primary efficacy outcome 
combined with either death from cardiovascular 
causes or death from any cause.
The principal safety outcome was the inci-
dence of adjudicated clinically relevant bleeding, 
which was defined as a composite of major or 
clinically relevant nonmajor bleeding. Bleeding 
was defined as major if it was overt and was as-
sociated with a decrease in hemoglobin of 2 g 
per deciliter or more or required a transfusion of 
2 or more units of blood, occurred in a critical 
site, or contributed to death.13 Clinically relevant 
nonmajor bleeding was defined as overt bleeding 
that did not meet the criteria for major bleeding 
but was associated with the need for medical 
intervention, contact with a physician, or inter-
ruption of the study drug or with discomfort or 
impairment of activities of daily life.14 Net clin-
ical benefit was determined on the basis of the 
composite of symptomatic recurrent venous 
thromboembolism or major bleeding. The criteria 
for adjudication of outcomes are provided in the 
Supplementary Appendix, available at NEJM.org.
Surveillance and Follow-up
Patients underwent assessment, in the clinic or 
by telephone, on days 5 through 12, 30, and 60 
after randomization and monthly thereafter while 
they were taking the study drug or every 3 months 
after discontinuing the study drug. All patients 
were to be contacted at month 12. Patients were 
instructed to report symptoms suggestive of re-
current venous thromboembolism or bleeding. 
Appropriate diagnostic testing, laboratory test-
ing, or both were required in patients with sus-
pected events.
Statistical Analysis
The study was designed as an event-driven trial 
to test the hypothesis that edoxaban would be 
noninferior to warfarin with respect to the pri-
mary efficacy outcome, with an upper limit of 
the confidence interval for the hazard ratio of 1.5 
and a two-sided alpha level of 0.05. This margin 
corresponds to retention of at least 70% of the 
treatment effect of warfarin.
Assuming equal efficacy of edoxaban and 
warfarin, we estimated that 220 events would 
need to occur for the study to have 85% power 
to show the noninferiority of edoxaban. When 
we determined that the targeted number of 
events was expected to be accrued, we set the 
date for concluding the study (study closure) 
such that the last patient who underwent ran-
domization would complete 6 months of study 
treatment and follow-up. Assuming a 3% inci-
dence of the primary efficacy outcome, we esti-
mated that we would have to enroll at least 7500 
patients.
All efficacy analyses were performed in the 
modified intention-to-treat population, which in-
cluded all patients who underwent randomization 
and received at least one dose of the study drug. 
The primary analysis included all efficacy out-
comes from randomization through the end of 
12 months or study closure (overall study period), 
regardless of the duration of the patient’s study 
treatment. The time to the first primary efficacy 
outcome was analyzed with the use of a Cox 
proportional-hazards model with stratification 
factors as covariates. In addition, the primary ef-
ficacy outcome was evaluated for the on-treatment 
period — the time during which the patients 
were receiving the study drug or within 3 days 
after the study drug was stopped or interrupted.
Analyses of bleeding outcomes included patients 
who received at least one dose of the study drug 
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(safety population). The time to clinically relevant 
bleeding during the on-treatment period was com-
pared with the use of the same Cox proportional-
hazards model that was used for the primary effi-
cacy outcome. Time-to-event curves were calculated 
with the use of the Kaplan–Meier method.
Prespecified subgroup analyses were per-
formed in subgroups defined according to the 
qualifying diagnosis and according to status 
with respect to right ventricular dysfunction 
(evidence or no evidence) in patients with pul-
monary embolism. The time in the therapeutic 
INR range was calculated with the use of stan-
dard methods,15 with the initial heparin lead-in 
period not included and with correction for 
planned interruptions. In all patients with pul-
monary embolism, N-terminal pro–brain natri-
uretic peptide (NT-proBNP) levels were mea-
sured at baseline (morning sample) in a core 
laboratory. Right ventricular dysfunction was 
defined as an NT-proBNP level of 500 pg per 
milliliter or higher.16,17 In addition, an indepen-
dent reviewer who was unaware of the treatment 
assignments evaluated right ventricular dimen-
sions on the qualifying computed tomographic 
scan in a random sample of 1002 patients. Right 
ventricular dysfunction was defined as the ratio 
of right ventricular diameter to left ventricular 
diameter of 0.9 or more.18,19
R esult s
Patients and Treatment
From January 2010 through October 2012, a total 
of 8292 patients were enrolled at 439 centers in 
37 countries (Fig. 1). The baseline characteristics 
of the patients were similar in the two study 
groups (Table 1). The median duration of heparin 
treatment after randomization was 7 days. De-
tails of the actual duration of treatment with the 
study drug are provided in Table S2 in the Sup-
plementary Appendix; 40% of patients were 
treated for 12 months. Adherence to edoxaban 
treatment was 80% or more in 99% of the pa-
tients in that group. Among patients receiving 
warfarin, the INR was in the therapeutic range 
for 63.5% of the time, above 3.0 for 17.6% of the 
time, and below 2.0 for 18.9% of the time.
Recurrent Venous Thromboembolism
A recurrence of venous thromboembolism dur-
ing the overall study period occurred in 130 of 
4118 patients (3.2%) in the edoxaban group and 
in 146 of 4122 patients (3.5%) in the warfarin 
group (hazard ratio with edoxaban, 0.89; 95% 
confidence interval [CI], 0.70 to 1.13; P<0.001 for 
noninferiority). The difference in risk (edoxaban 
minus warfarin) was −0.39 percentage points 
(95% CI, −1.16 to 0.39). The types and time 
8292 Patients underwent randomization
4143 Were assigned to receive heparin–
edoxaban
4149 Were assigned to receive
heparin–warfarin
25 Did not receive heparin–
edoxaban
27 Did not receive heparin–
warfarin
4118 Were included in modified intention-
to-treat and safety analyses
181 Did not complete the overall study
period
132 Died
36 Withdrew consent
7 Were lost to follow-up
6 Had other reasons
4122 Were included in modified intention-
to-treat and safety analyses
167 Did not complete the overall study
period
126 Died
34 Withdrew consent
4 Were lost to follow-up
3 Had other reasons
Figure 1. Randomization and Follow-up.
The modified intention-to-treat and safety analyses included all patients who underwent randomization and re-
ceived at least one dose of the study drug.
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course of recurrent venous thromboembolic 
events are shown in Table 2 and Figure 2.
The upper limits of the 95% confidence inter-
vals of the hazard ratios for recurrent venous 
thromboembolism in patients who presented with 
deep-vein thrombosis or pulmonary embolism 
did not exceed the prespecified margin of 1.5 
(Table 2). Among patients with pulmonary em-
bolism and evidence of right ventricular dysfunc-
tion (NT-proBNP level of ≥500 pg per milliliter), 
Table 1. Demographic and Clinical Characteristics of the Patients.*
Characteristic All Patients
Patients with  
Deep-Vein Thrombosis Only
Patients with  
Pulmonary Embolism
Edoxaban 
(N = 4118)
Warfarin 
(N = 4122)
Edoxaban 
(N = 2468)
Warfarin 
(N = 2453)
Edoxaban 
(N = 1650)
Warfarin 
(N = 1669)
Age
Mean — yr 55.7±16.3 55.9±16.2 54.7±16.0 54.9±15.9 57.1±16.6 57.4±16.5
≥75 yr — no. (%) 560 (13.6) 544 (13.2) 282 (11.4) 273 (11.1) 278 (16.8) 271 (16.2)
Male sex — no. (%) 2360 (57.3) 2356 (57.2) 1497 (60.7) 1481 (60.4) 863 (52.3) 875 (52.4)
Weight — no. (%)
≤60 kg† 524 (12.7) 519 (12.6) 320 (13.0) 304 (12.4) 204 (12.4) 215 (12.9)
>100 kg 611 (14.8) 654 (15.9) 360 (14.6) 379 (15.5) 251 (15.2) 275 (16.5)
Creatinine clearance ≥30 to ≤50 ml/
min — no. (%)†
268 (6.5) 273 (6.6) 152 (6.2) 153 (6.2) 116 (7.0) 120 (7.2)
Patients receiving 30 mg  
of edoxaban at randomiza-
tion — no. (%)†
733 (17.8) 719 (17.4) 425 (17.2) 411 (16.8) 308 (18.7) 308 (18.5)
Anatomical extent of qualifying event 
— no. (%)‡
Limited — — 603 (24.4) 596 (24.3) 128 (7.8) 123 (7.4)
Intermediate — — 795 (32.2) 773 (31.5) 679 (41.2) 682 (40.9)
Extensive — — 1035 (41.9) 1049 (42.8) 743 (45.0) 778 (46.6)
Not assessable — — 35 (1.4) 35 (1.4) 100 (6.1) 86 (5.2)
Concomitant DVT — no. (%) — — — — 410 (24.8) 404 (24.2)
Baseline NT-proBNP — no. (%)
Patients with measurement — — — — 1484 (89.9) 1505 (90.2)
Patients with level ≥500 pg/ml — — — — 454 (27.5) 484 (29.0)
Right ventricular dysfunction  
— no./total no. (%)§
— — — — 172/498 (34.5) 179/504 (35.5)
Causes of DVT or PE — no. (%)¶
Unprovoked 2713 (65.9) 2697 (65.4) 1666 (67.5) 1655 (67.5) 1047 (63.5) 1042 (62.4)
Temporary risk factor 1132 (27.5) 1140 (27.7) 655 (26.5) 655 (26.7) 477 (28.9) 485 (29.1)
Cancer 378 (9.2) 393 (9.5) 209 (8.5) 205 (8.4) 169 (10.2) 188 (11.3)
Previous VTE 784 (19.0) 736 (17.9) 416 (16.9) 414 (16.9) 368 (22.3) 322 (19.3)
* Plus–minus values are means ±SD. There were no significant differences between the edoxaban group and the warfarin group in any of the 
characteristics listed here. DVT denotes deep-vein thrombosis, NT-proBNP N-terminal pro–brain natriuretic peptide, PE pulmonary embo-
lism, and VTE venous thromboembolism.
† Patients with a body weight below 60 kg or a creatinine clearance of 30 to 50 ml per minute, as well as patients who were receiving concom-
itant P-glycoprotein inhibitors such as verapamil or quinidine, received 30 mg instead of 60 mg of edoxaban to maintain similar exposure to 
the cohort receiving 60 mg.
‡ Among patients with DVT alone, limited refers to an event in which the most proximal site was the popliteal vein; intermediate, an event in 
which the most proximal site was the superficial femoral vein; and extensive, an event in which the most proximal site was the common 
femoral or iliac vein. Among patients with PE, limited refers to involvement of 25% or less of the vasculature of a single lobe; intermediate, 
involvement of more than 25% of the vasculature of a single lobe or multiple lobes with involvement of 25% or less of the entire vascula-
ture; and extensive, involvement of multiple lobes with 25% or more of the entire vasculature.
§ Right ventricular function was assessed by calculating the ratio of the right ventricular diameter to the left ventricular diameter on a four-
chamber view of the qualifying index pulmonary embolism on a computed tomographic scan.
¶ A patient could have multiple risk factors. Temporary risk factors included recent surgery, trauma, immobilization, or use of estrogen.
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Table 2. Clinical Outcomes during Overall Study Period and On-Treatment Period.*
Outcome
Edoxaban  
(N = 4118)
Warfarin  
(N = 4122)
Hazard Ratio with 
Edoxaban (95% CI) P Value
Primary efficacy outcome: first recurrent VTE or 
VTE-related death — no./total no. (%)
All patients
Event during overall study period 130/4118 (3.2) 146/4122 (3.5) 0.89 (0.70–1.13) <0.001  
(for noninferiority)
Fatal PE 4/4118 (0.1) 3/4122 (0.1)
Death, with PE not ruled out 20/4118 (0.5) 21/4122 (0.5)
Nonfatal PE with or without DVT 49/4118 (1.2) 59/4122 (1.4)
DVT alone 57/4118 (1.4) 63/4122 (1.5)
Event during on-treatment period 66/4118 (1.6) 80/4122 (1.9) 0.82 (0.60–1.14) <0.001  
(for noninferiority)
Patients with index DVT 2468/4118 (59.9) 2453/4122 (59.5)
Event during overall study period 83/2468 (3.4) 81/2453 (3.3) 1.02 (0.75–1.38)
Event during on-treatment period 48/2468 (1.9) 50/2453 (2.0) 0.96 (0.64–1.42)
Patients with index PE 1650/4118 (40.1) 1669/4122 (40.5)
Event during overall study period 47/1650 (2.8) 65/1669 (3.9) 0.73 (0.50–1.06)
Event during on-treatment period 18/1650 (1.1) 30/1669 (1.8) 0.60 (0.34–1.08)
Safety outcome during on-treatment period  
— no. (%)
Primary safety outcome: first major or clinically  
relevant nonmajor bleeding
349 (8.5) 423 (10.3) 0.81 (0.71–0.94) 0.004  
(for superiority)
Major bleeding 56 (1.4) 66 (1.6) 0.84 (0.59–1.21) 0.35  
(for superiority)
Fatal 2 (<0.1) 10 (0.2)
Intracranial 0 6 (0.1)
Gastrointestinal 1 (<0.1) 2 (<0.1)
Retroperitoneal 0 1 (<0.1)
Other 1 (<0.1) 1 (<0.1)
Nonfatal in critical site 13 (0.3) 25 (0.6)
Intracranial 5 (0.1) 12 (0.3)
Retroperitoneal 0 3 (0.1)
Other 8 (0.2) 10 (0.2)
Nonfatal in noncritical site 41 (1.0) 33 (0.8)
Clinically relevant nonmajor bleeding 298 (7.2) 368 (8.9) 0.80 (0.68–0.93) 0.004  
(for superiority)
Any bleeding 895 (21.7) 1056 (25.6) 0.82 (0.75–0.90) <0.001  
(for superiority)
Other adverse event — no. (%)
Any adverse event occurring during  
on-treatment period
2821 (68.5) 2928 (71.0)
Any serious adverse event 503 (12.2) 544 (13.2)
Any serious adverse event leading to permanent dis-
continuation of the study drug
121 (2.9) 105 (2.5)
Any drug-related adverse event leading to permanent 
discontinuation of the study drug
41 (1.0) 51 (1.2)
* The primary efficacy and safety outcomes were assessed by means of time-to-first-event analyses. Patients could have more than one event. 
The overall study period was 12 months; the on-treatment period included the time during which the patients were receiving the study drug 
or within 3 days after the study drug was stopped or interrupted.
The New England Journal of Medicine 
Downloaded from nejm.org on September 16, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;15 nejm.org october 10, 20131412
recurrent venous thromboembolism occurred in 
15 of 454 patients (3.3%) in the edoxaban group 
and in 30 of 484 patients (6.2%) in the warfarin 
group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). 
Similar results were observed among patients 
with right ventricular dysfunction as assessed by 
means of computed tomography (hazard ratio, 
0.42; 95% CI, 0.15 to 1.20).
Among patients who qualified for the 30-mg 
dose of edoxaban, recurrent venous thrombo-
embolism occurred in 22 of 733 patients (3.0%)
re ceiving edoxaban, as compared with 30 of the 
719 patients (4.2%) receiving warfarin (hazard 
ratio, 0.73; 95% CI, 0.42 to 1.26). The hazard 
ratios for recurrent venous thromboembolism in 
the other prespecified subgroups are shown in 
Figure S1 in the Supplementary Appendix.
Bleeding Outcomes
Clinically relevant bleeding (major or nonmajor) 
occurred in 349 of 4118 patients (8.5%) in the 
edoxaban group and in 423 of 4122 patients 
(10.3%) in the warfarin group (hazard ratio, 0.81; 
95% CI, 0.71 to 0.94; P = 0.004 for superiority). 
The difference in risk (edoxaban minus warfarin) 
was −1.8 percentage points (95% CI, −3.04 to 
−0.53). Major bleeding occurred in 56 patients 
(1.4%) in the edoxaban group and in 66 patients 
(1.6%) in the warfarin group (hazard ratio, 0.84; 
95% CI, 0.59 to 1.21). The clinical presentation 
and time course of bleeding events are provided 
in Table 2 and Figure 3.
Among patients who qualified for the 30-mg 
dose of edoxaban, clinically relevant bleeding 
occurred in 58 of 733 patients (7.9%) who re-
ceived edoxaban, and in 92 of the 719 patients 
(12.8%) who received warfarin (hazard ratio, 
0.62; 95% CI, 0.44 to 0.86). Major bleeding oc-
curred in 11 patients (1.5%) in the edoxaban 
group and in 22 patients (3.1%) in the warfarin 
group (hazard ratio, 0.50; 95% CI, 0.24 to 1.03). 
The hazard ratios for bleeding in the other 
prespecified subgroups are provided in Figure S2 
in the Supplementary Appendix.
Deaths and Other Adverse Events
The number and causes of death, as well as results 
with respect to the net clinical benefit, are shown 
in Table S3 in the Supplementary Appendix. 
There were 21 acute coronary events in the edox-
aban group (0.5%) and 16 in the warfarin group 
(0.4%). The rates of other adverse outcomes were 
also similar in the two groups. (Table 2, and Ta-
ble S3 in the Supplementary Appendix).
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Figure 2. Kaplan–Meier Cumulative Event Rates for the Primary Efficacy Outcome.
Kaplan–Meier curves are shown for the first occurrence of the primary efficacy outcome of adjudicated symptomat-
ic recurrent venous thromboembolism (VTE) — a composite of deep-vein thrombosis or nonfatal or fatal pulmo-
nary embolism — in the overall study period. The inset shows the same data on an enlarged y axis.
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Discussion
In this large, double-blind study involving pa-
tients with venous thromboembolism, treatment 
with heparin followed by oral edoxaban once 
daily, as compared with standard therapy, was 
noninferior with respect to efficacy and superior 
with respect to bleeding. We succeeded in enroll-
ing patients across a broad spectrum of venous 
thromboembolic manifestations, ranging from 
limited proximal deep-vein thrombosis to severe 
pulmonary embolism, and the relative efficacy 
was observed throughout. In analyses of safety, 
the results were consistent with respect to both 
major bleeding and clinically relevant nonmajor 
bleeding, with fewer fatal and intracranial bleeds 
in the edoxaban group (Table 2), although the 
between-group difference with respect to major 
bleeding did not reach statistical significance.
Efficacy was evaluated at 12 months of fol-
low-up, regardless of the duration of treatment 
— a study design that was different from that of 
earlier studies.5-8 The design of the Hokusai-VTE 
study, as compared with a design calling for on-
treatment analyses only, allowed for a better 
understanding of the outcomes that may be ex-
pected in clinical practice. In the on-treatment 
analysis, we observed low rates of recurrence 
that were similar to those seen in contemporary 
studies.5-8 In our study, the relative efficacy of 
edoxaban was not limited to patients receiving 
medication, but it was evident even among those 
who stopped treatment before 12 months (Fig. 2).
Some aspects of our trial warrant comment. 
Three recent studies focused on a single-drug 
approach for all treatment phases.6-8 Thus, the 
use of the traditional sequence of a heparin lead-
in followed by an oral agent may be considered 
a limitation of the Hokusai-VTE study. However, 
given the global acceptance of, and confidence in, 
initial parenteral treatment, the heparin lead-in 
encouraged investigators to enroll a high propor-
tion of patients with severe grades of venous 
thromboembolism. When designing the study, we 
anticipated that a considerable proportion of pa-
tients with right ventricular dysfunction due to 
pulmonary embolism would be included. We 
measured NT-proBNP levels in all patients with 
pulmonary embolism and assessed right ven-
tricular dimensions by means of computed to-
mography in a random subgroup of 1002 of 
these patients. Approximately one third had 
right ventricular dysfunction. There was a reduc-
tion in recurrences among patients with elevated 
NT-proBNP levels in the edoxaban group, and 
this finding was supported by the analysis of 
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Figure 3. Kaplan–Meier Cumulative Event Rates for the Principal Safety Outcome.
The principal safety outcome was the incidence of adjudicated clinically relevant bleeding, which was defined as a 
composite of major or clinically relevant n nmajor bleeding. The inset shows the same data on an enlarged y axis.
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patients with right ventricular dysfunction as 
assessed by means of computed tomography.
The study design aimed to address concerns 
that new oral anticoagulants may confer a higher 
risk of bleeding among patients with renal im-
pairment and low body weight.12 We identified 
approximately one fifth of patients with these 
risk factors. Halving of the daily dose of edoxa-
ban to 30 mg maintained efficacy with signifi-
cantly less bleeding than that observed in the 
warfarin group.
To ensure best practice with the comparator, 
the quality of warfarin therapy was proactively 
monitored throughout the study. This resulted in 
an overall time in the therapeutic range of 
63.5%, which is a higher percentage of time in 
the therapeutic range than the 40 to 50% seen 
in registries of clinical practice.20-22 Our find-
ings are likely to be generalizable. In this global 
study, we included patients with both provoked 
and unprovoked venous thromboembolism, and 
treatment durations varied from 3 to 12 months 
at the discretion of the treating physician. Loss 
to follow-up was very low (<0.2%), as was the 
rate of withdrawal of consent (<0.9%).23
In conclusion, the Hokusai-VTE study showed 
that in a broad spectrum of patients with venous 
thromboembolism, including those with severe 
pulmonary embolism, edoxaban administered 
once daily after initial heparin was noninferior 
to standard therapy with warfarin after initial 
heparin, with significantly less bleeding.
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